Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022
15 août 2022 21h46 HE
|
Mydecine Innovations Group Inc.
DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of...
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
19 juil. 2022 07h00 HE
|
Mydecine Innovations Group Inc.
DENVER, July 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
17 juin 2022 07h00 HE
|
Mydecine Innovations Group Inc.
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental...
Mydecine Provides Company Update; Welcomes New Board Member
09 juin 2022 07h00 HE
|
Mydecine Innovations Group Inc.
DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
Mydecine Announces First Quarter 2022 Financial Results and Highlights
16 mai 2022 21h28 HE
|
Mydecine Innovations Group Inc.
DENVER, May 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment...
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
31 mars 2022 22h03 HE
|
Mydecine Innovations Group Inc.
MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families DENVER, March ...
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
24 mars 2022 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, March 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology company aiming to transform the...
Mydecine To Attend March Investor Conferences
03 mars 2022 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, March 03, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
01 mars 2022 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, March 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of...
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules
16 févr. 2022 07h30 HE
|
Mydecine Innovations Group Inc.
DENVER, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the...